9 hidden AI stocks set to thrive in Trump’s new era

AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)

Jonathan D. Root net worth and biography

Jonathan Root Biography and Net Worth

Director of Edgewise Therapeutics

Jon Root, M.D., serves as a member of our board of directors and is a General Partner at U.S. Venture Partners, having joined the firm in 1995 as a Ewing Marion Kauffman Fellow in venture capital. Before USVP, Dr. Root was Assistant Professor of Neurology and Director of the Neurology-Neurosurgery Special Care Unit at The New York Hospital-Cornell Medical Center in New York City. He is board certified in neurology. In addition to Edgewise, Dr. Root is currently on the boards of USVP portfolio companies Cleave Biosciences, eFFECTOR Therapeutics, HealthJoy, Inari Medical, Nuvaira, Okami Medical, Omada Health, Ribon Therapeutics, Route 92 Medical and Swoop. Dr. Root is a former board member for the National Venture Capital Association (NVCA). Dr. Root holds an A.B. in Economics from Dartmouth College, an M.D. from the University of Florida College of Medicine, and an M.B.A. from Columbia University.

What is Jonathan D. Root's net worth?: The estimated net worth of Jonathan D. Root is at least $503,125.00 as of March 30th, 2021. Dr. Root owns 15,625 shares of Edgewise Therapeutics stock worth more than $503,125 as of November 24th. This net worth approximation does not reflect any other investments that Dr. Root may own. Learn More about Jonathan D. Root's net worth.
How do I contact Jonathan D. Root?: The corporate mailing address for Dr. Root and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Jonathan D. Root's contact information.
Has Jonathan D. Root been buying or selling shares of Edgewise Therapeutics?: Jonathan D. Root has not been actively trading shares of Edgewise Therapeutics during the last quarter. Most recently, on Tuesday, March 30th, Jonathan D. Root bought 15,625 shares of Edgewise Therapeutics stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director now directly owns 15,625 shares of the company's stock, valued at $250,000. Learn More on Jonathan D. Root's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

Jonathan D. Root Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/30/2021	Buy	15,625	$16.00	$250,000.00	15,625

Jonathan D. Root Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $32.20

$31.76

$32.72

50 Day Range

MA: $30.92

$16.86

$36.62

2 Week Range

Now: $32.20

$5.93

$38.12

Volume

353,056 shs

Average Volume

695,699 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

9 hidden AI stocks set to thrive in Trump’s new era

From StockEarnings | Ad